VGA039 : Vega Therapeutics begins clinical trial of Von Willebrand disease candidate

Vega Therapeutics has launched the clinical trial program for VGA039, an investigational antibody therapy for Von Willebrand disease (VWD), a bleeding disorder in which the ... Read More